Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
| Title: | Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. |
|---|---|
| Authors: | Kondili LA; Gaeta GB; Brunetto MR; Di Leo A; Iannone A; Santantonio TA; Giammario A; Raimondo G; Filomia R; Coppola C; Amoruso DC; Blanc P; Del Pin B; Chemello L; Cavalletto L; Morisco F; Donnarumma L; Rumi MG; Gasbarrini A; Siciliano M; Massari M; Corsini R; Coco B; Madonia S; Cannizzaro M; Zignego AL; Monti M; Russo FP; Zanetto A; Persico M; Masarone M; Villa E; Bernabucci V; Taliani G; Biliotti E; Chessa L; Pasetto MC; Andreone P; Margotti M; Brancaccio G; Ieluzzi D; Borgia G; Zappulo E; Calvaruso V; Petta S; Falzano L; Quaranta MG; Weimer LE; Rosato S; Vella S; Giannini EG. |
| Contributors: | Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG. |
| Publication Year: | 2017 |
| Collection: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| Subject Terms: | DAA; HCV; resistance |
| Description: | Background Few data are available on the virological and clinical outcomes of advanced liver disease patients retreated after first-line DAA failure. Aim To evaluate DAA failure incidence and the retreatment clinical impact in patients treated in the advanced liver disease stage. Methods Data on HCV genotype, liver disease severity, and first and second line DAA regimens were prospectively collected in consecutive patients who reached the 12-week post-treatment and retreatment evaluations from January 2015 to December 2016 in 23 of the PITER network centersResults Among 3,830 patients with advanced fibrosis (F3) or cirrhosis, 139 (3.6%) failed to achieve SVR. Genotype 3, bilirubin levels >1.5mg/dl, platelet count |
| Document Type: | article in journal/newspaper |
| File Description: | ELETTRONICO |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/28977040; info:eu-repo/semantics/altIdentifier/wos/WOS:000412163100039; volume:12; issue:10; firstpage:1; lastpage:13; numberofpages:13; journal:PLOS ONE; http://hdl.handle.net/11585/674414; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0185728 |
| DOI: | 10.1371/journal.pone.0185728 |
| Availability: | http://hdl.handle.net/11585/674414; https://doi.org/10.1371/journal.pone.0185728; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0185728 |
| Rights: | info:eu-repo/semantics/openAccess |
| Accession Number: | edsbas.4F635972 |
| Database: | BASE |